Teligent Slammed By FDA Warning Letter

Criticized For Lax Approach To Complaint Handling And Stability Testing

Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.

Warning Rubber Stamp
FDA Says Teligent Needs To Up Its Complaint Handling Game • Source: Shutterstock

The US Food and Drug Administration has rebuked New Jersey drug manufacturer Teligent for lax handling of product complaints associated with generic topical products and for pulling stability samples without immediately testing them. The firm was also cited in a recent warning letter for not filing field alert reports in a timely manner.

The warning letter was posted on 10 December and follows up on an inspection of the firm’s site in Buena,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business